Investors
Founded in November 2012, ObsEva is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious conditions that compromise a woman’s reproductive health and pregnancy. We believe our expertise has led to the development of new and innovative therapies that have the potential to improve patient outcomes in reproductive health.
press release
November 7, 2018
Geneva, Switzerland and Boston, MA – November 7, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…
Read morepress release
October 31, 2018
(GLOBE NEWSWIRE via COMTEX) –Geneva, Switzerland and Boston, MA –October 31, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN),…
Read morepress release
October 9, 2018
Abstract featuring-IMPLANT2 data awarded Prize Paper by Society for Assisted Reproductive Technology (SART) Nolasiban treatment shown to significantly increase Live Birth Rate…
Read moreJune 29, 2023
May 18, 2022
ObsEva Announces Delisting from SIX Swiss Exchange and Exemption from Certain Obligations Associated with the Maintenance of Listing
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 –…
Read moreMedia
Chemin des Aulx,12
1228, Plan-Les-Ouates, Geneva, Switzerland
+41 (0)22 552 3840